Progress in antiandrogen design targeting hormone binding pocket to circumvent mutation based resistance by Xiaohong Tian et al.
REVIEW
published: 24 March 2015
doi: 10.3389/fphar.2015.00057






Università Cattolica del Sacro Cuore,
Italy
Mohamed Diwan M. AbdulHameed,
Department of Defense Biotechnology
High Performance Computing
Software Applications Institute, USA
*Correspondence:
Jinming Zhou,
Immunology, Institute of Medicinal
Biotechnology Chinese Academy of




This article was submitted to
Experimental Pharmacology and Drug
Discovery, a section of the journal
Frontiers in Pharmacology
Received: 31 December 2014
Paper pending published:
10 February 2015
Accepted: 05 March 2015
Published: 24 March 2015
Citation:
Tian X, He Y and Zhou J (2015)
Progress in antiandrogen design
targeting hormone binding pocket to
circumvent mutation based
resistance. Front. Pharmacol. 6:57.
doi: 10.3389/fphar.2015.00057
Progress in antiandrogen design
targeting hormone binding pocket to
circumvent mutation based
resistance
Xiaohong Tian 1, Yang He 2 and Jinming Zhou 2*
1 Lady Davis Institute, Jewish General Hospital, Mcgill University, Montreal, QC, Canada, 2 Immunology, Institute of Medicinal
Biotechnology Chinese Academy of Medical Science, Beijing, China
Androgen receptor (AR) plays a critical role in the development and progression
of prostate cancer (PCa). Current clinically used antiandrogens such as flutamide,
bicalutamide, and newly approved enzalutamide mainly target the hormone binding
pocket (HBP) of AR. However, over time, drug resistance invariably develops and
switches these antiandrogens from antagonist to agonist of the AR. Accumulated
evidence indicates that AR mutation is an important cause for the drug resistance. This
review will give an overview of the mutation based resistance of the current clinically
used antiandrogens and the rational drug design to overcome the resistance, provides a
promising strategy for the development of the new generation of antiandrogens targeting
HBP.
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Introduction
Prostate cancer (PCa) is one of the most common cancer and the second leading cause of can-
cer death in men in the western countries (Jemal et al., 2011). AR, a member of nuclear receptor
family that is activated by binding of androgens (Roy et al., 1999), plays an important role in pro-
moting the development of PCa (Dong et al., 2005). Moreover, it has been commonly agreed that
AR expression and signaling remains intact as the disease evolves from androgen-sensitive can-
cer to castration-resistant prostate cancer (CRPC) which are still dependent on AR signaling axis
(Jenster, 1999; Taplin, 2007). Thus, AR has become the most important therapeutic target for the
treatment of PCa (Aragon-Ching, 2014; Carver, 2014; Culig, 2014).
Through blocking AR signaling, androgen-deprivation therapy (ADT) (via surgical or chemi-
cal castration) has been remaining the mainstay for the treatment of advanced PCa since 1940s.
(Ruckle and Oesterling, 1993; Lubeck et al., 2001; Ryan and Small, 2006; Cannata et al., 2012).
Normally, ADT reduces 95% of testosterone levels. However the androgen stimulus is still per-
sisting as a result of circulating androgens produced by intracrine steroidogenesis (Montgomery
et al., 2008). Thus, by using antiandrogens as an adjuvant treatment of ATD to block the intracrine
steroidogenesis, may eventually delay or prevent the progression to CRPC. AR antiandrogens
prevent androgens from carrying out their biological activity by directly binding and blocking
the AR LBD, or by inducing repressive activity (Maeda and Usami, 2002; Gillatt, 2006). Current
clinically used antiandrogens such as flutamide (Goldspiel and Kohler, 1990), bicalutamide (Black-
ledge et al., 1997), and newly approved enzalutamide (Semenas et al., 2013) mainly target the
HBP of the AR LBD. These approved antiandrogens have greatly improved the survival and life
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quality of the PCa patients. However, after the initially effective
response, most tumors progress to CRPC under the treatment of
antiandrogens, and no curative therapy is available nowadays.
It has been wildly accepted that the acquired AR mutation is
an important cause for the drug resistance of PCa toward antian-
drogens. For example, T877A mutant would turn flutamide into
AR agonist (Bohl et al., 2005a), and W741C would turn bica-
lutamide into AR agonist. (Bohl et al., 2005b). Therefore, the
development of novel antiandrogens to circumvent the muta-
tion based resistance is highly demanded. Fortunately, up to now,
several effective strategies, especially the rational drug design,
have been applied in the design of the antiandrogens targeting
HBP of the AR, and several promising agents have been obtained
(Trendel, 2013). This review will give an overview of the muta-
tion based resistance of the current clinically used antiandrogens
and the rational drug design to overcome the resistance, which
provides a promising strategy for the development of the new
generation of antiandrogens targeting the AR HBP.
Structure and Function of AR
As a member of nuclear receptor family, AR possesses a modular
organization characteristic to all of the nuclear receptors. There
FIGURE 1 | (A) AR gene consists of 8 exons encoding the androgen
receptor with a gene product of typical size of 919 amino acids. AR
is comprised of an N-terminal domain (NTD), a central DNA binding
domain (DBD), a short-hinge region, and a C-terminal LBD. (B) LBD
comprises a 12 helical structure that encloses a central hormone
binding pocket (HBP), a second activation function domain (AF2) that
is located at the carboxy-terminal end of the LBD, and a recently
discovered binding site, Binding function 3 (BF3). The adopted
conformation of H12 are unambiguously associated with the
molecular mechanism of action of ligands bound to the HBP. (C) As
shown in compex structure of dihydrotestosterone (DHT) and
AR-LBD, the AR HBP is primarily composed of hydrophobic residues
(green ball) that can form strong nonpolar interactions with DHT. The
protein-ligand anchoring can be additionally stabilized by a network
of hydrogen bonds (blue dashed line) involving R752, Q711, N705,
and T877 polar residues.
is only one AR gene identified in human so far, consisting of
8 exons encoding the AR with a typical size of 919 amino
acids (Werner et al., 2006; Gao, 2010). AR is comprised of
an N-terminal domain (NTD), a central DNA binding domain
(DBD), a short-hinge region, and a C-terminal LBD (Figure 1A).
Among these domains, the NTD, as an intrinsically disordered
region, is the least conserved domain in AR, which contains
a transcription activation domain: activation function 1 (AF1)
that regulates gene transcription in a ligand-independent fash-
ion (Yuan et al., 2001). The adjacent DBD is the most conserved
domain, composed of two cysteine-rich zinc-finger motifs, medi-
ating AR binding to recognition elements of specific genes in
DNA. The hinge region bridges between the DBD and the LBD
and harbors a nuclear localization signal (NLS). The C-terminal
LBD (Figure 1B) comprises a 12 helical structure that encloses a
central hormone binding pocket (HBP), a second activation func-
tion domain (AF2) that is located at the carboxy-terminal end of
the LBD and mediates ligand dependent transactivation, and a
recently discovered binding site, Binding function 3 (BF3). Helix
12 (H12) is the most flexible part of AR, and conformational
changes of H12 are unambiguously associated with the molecular
mechanism of action of ligands bound to the HBP (Caboni and
Lloyd, 2013). The HBP is primarily composed of hydrophobic
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residues that can form strong nonpolar interactions with ligands.
The protein-ligand anchoring can be additionally stabilized by
a network of hydrogen bonds involving polar residues such as
R752, Q711, N705, and T877 (Figure 1C).
Androgen exerts its biological effects through binding the
HBP of AR. Upon binding, H12 is repositioned to cover the
HBP, triggering agonist-induced conformational change in the
LBD, results in the formation of AF2. The AR dissociates from
heat shock proteins (HSPs), homodimerizes and translocats into
the nucleus where it binds ARE sites of DNA, directly regu-
lates targeting genes transcription in the presence of coactivator
which binds to AF2, promoting the recruitment of RNA poly-
merase II, triggering the transcription process (Pratt and Toft,
1997; Heinlein and Chang, 2002; Shang et al., 2002). In addi-
tion to the classic genomic actions, the nongenomic actions of
the androgens have also been observed in various tissues and
characterized by the lack of immediate activation of transcrip-
tion/translation processes, due to the rapidity of action that is
mainly mediated by the activation of cytoplasmic and/or plasma
membrane-associated receptors and downstream signaling path-
ways (Norman et al., 2004), which contributes to the overall
effects of androgen stimulation, along with the classic genomic
actions.
AR plays an important role in promoting the development of
PCa (Dong et al., 2005). Accumulated evidence shows that the AR
signaling still contributes to CRPC through several mechanisms,
including AR protein overexpression, acquired mutations of AR
which disables the antagonistic activity of antiandrogen, aberrant
expression of AR co-regulators and alternative AR activation by
cytokines and growth factors in the absence of androgens, and
the expression of AR splice variants (ARvs) lacking LBD such as
AR-V7 and ARv567. In addition, the TMPRSS-ERG fusion also
plays an important role in PCa progression by disrupting the
AR lineage-specific differentiation through gene rearrangements,
which leads to an EZH2-mediated de-differentiation of cells. The
most common one is the fusion of the 3′ region of ERG with
the 5′ region of the highly AR-regulated TMPRSS2 gene. ERG
rearrangements have been identified in 40–60% of PCa (Tomlins
et al., 2005).
AR Acquired Mutations Driven Drug
Resistance in PCa
Current clinically used antiandrogens mainly target the
HBP. There are two types of antiandrogens: the steroidal
antiandrogens and the non-steroidal antiandrogens. Several
steroidal anti-androgens (cyproterone acetate, megestrol acetate,
and medroxyprogesterone acetate) are initially used for the
androgen blockade in patients. However, severe drawbacks
such as hepatotoxicity, interference with libido and potency,
cardiovascular side effects and low efficacy have limited their
clinical use. The later developed non-steroidal antiandrogens
including the first-generation antiandrogens such as flutamide,
bicalutamide, nilutamide, and the second-generation com-
pounds: enzalutamide and ARN509. These non-steroidal
antiandrogens which avoid the typical constraints of the steroidal
antiandrogens, have been widely used in clinical nowadays.
However, after initially effective response, approximately 50% of
patients whose cancer started to grow again under the treatment
of antiandrogens, the cancer has been observed to regress by
simply stopping the antiandrogen, which referred to the Anti-
AndrogenWithdrawal Response (AAWR) (Paul and Breul, 2000;
Sartor et al., 2008). It has been widely accepted that the acquired
mutations of AR in PCa under the pressure of the antiandrogen
is responsible for such phenomenon, which turns antiandrogens
from AR antagonist to AR agonist and causing drug resistance
(Figure 2A).
One particular AR mutation is the T877A in the LBD of AR,
which actually results in paradoxical activation by hydroxyflu-
tamide, an active metabolite of flutamide. Several variations of
the 877 mutations have been discovered: T877S, T877C, and
T877G. The T877A mutation along with H874Y mutation allows
AR to be activated by cortisol. The W741C and W741L AR
mutant are activated by bicalutamide. Another mutation, L701H,
enhances cell proliferation upon stimulation of IL-6. Addition-
ally, V715M, along with T877A, L701H, and H874Y, were iden-
tified in LNCaP cells treated with bisphenol A. Besides, a muta-
tion at Q640S produces a truncated AR resulting in constitutive
activation in the absence of ligand (Grasso et al., 2012; Tren-
del, 2013). Recently, a novel mutant F876L which turned enza-
lutamide and ARN509 from AR antagonist to AR agonist was
identified in preclinical models and in the patients being treated
with ARN509 (Joseph et al., 2013).
The mechanisms of mutant-driven conversion of antiandro-
gen from AR antagonist to AR agonist have been verified by the
biological structural data. The crystal structure of T877A AR-
LBD in complex with OHF (PDB-ID, 2ax6) demonstrates that
the H12 adopts the agonistic conformation, which elucidates that
the T877A mutation converts the OHF from an antagonist to an
agonist (Figure 2B) (Bohl et al., 2005a). Another crystal structure
(PDB-ID, 1z95) provides the structural evidence that W741L AR
mutant switches bicalutamide to an agonist (Figure 2C) (Bohl
et al., 2005b). A structural superimposition of these two struc-
tures with the AR-LBD structure bound with DHT conferred
perfect alignments of the H12 with the RMSD (root mean square
deviation) values of 0.28 and 0.48 Å, respectively, which con-
firmed that the mutant-driven conversion from the AR antago-
nist to AR agonist (Figure 2D). However, the mechanism under
the antagonist-agonist conversion of ligands remains elusive.
Rational Antiandrogen Design to
Circumvent Drug Resistance Driven by AR
Acquired Mutations
As mentioned previously, PCa is continually undergoing AR
mutations that switch the antiandrogen from AR antagonist to
AR agonist and eventually relapses to lethal CRPC. Thus the
rational development of novel antiandrogens based on the AR
acquiredmutations driven drug resistant seems like ongoing run-
ning race and remains a big challenge (Josan and Katzenellenbo-
gen, 2013). Up to now, several effective strategies, especially the
rational drug design, have been applied in the development of the
antiandrogens targeting HBP of AR (Figure 3).
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FIGURE 2 | (A) Several acquired mutations drive drug resistance:
T877A mutant turns hydroxyflutamide (OHF), an active metabolite of
antiandrogen flutamide in AR agonist; W741C or W741L converts
bicalutamide (BIC) into AR agonist; a novel mutant F876L was
identified inducing the resistance to enzalutamide and ARN509. (B)
The crystal structure (PDB-ID: 2ax6) of T877A LBD/ hydroxyflutamide
(OHF) shows adopting a agonistic conformation; (C) the crystal
structure (PDB-ID: 1z95) of W741L LBD/ bicalutamide (BIC) shows
adopting a agonistic conformation; (D) A superimposition of T877A
LBD/OHF and W741L LBD/ BIC structures with the LBD structure
bound with DHT (PDB-ID: 1i37) by sequence conferred a perfect
alignment of the H12 with the RMSD value of 0.28 and 0.48 Å,
respectively, which confirmed the mutant-driven conversion from
antiandrogen to AR agonist.
FIGURE 3 | Rational antiandrogen design strategy to combat the mutation driven drug resistance: (A) Bulky group strategy; (B) Structure based
antiandrogen design; (C) Conjugate strategy.
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Bulky Group Strategy
Considerating that the agonistic conformation of H12 is like a
lid enclosing the HBP, designing compounds bearing an extended
bulky arm to displaceH12 (Figure 3A) is an effective strategy. For
example, based on the structure of bicalutamide, several deriva-
tives with an extended aryl sulfone core were designed and pre-
pared. Among them, compounds 1–3 (Figure 4) showed potent
antagonistic activity in all three mutations (T877A, W741L, and
W741C) as well as wild-type AR (McGinley and Koh, 2007). Sim-
ilarly, a series of flutamide analogs with bulky groups were also
obtained and some of them circumvent the resistant mutation to
their parent compound (Duke et al., 2011). Other bulky group
antiandrogens with novel scaffolds were also reported. Zhou et
al have developed a novel antiandrogen 4 (Figure 4) with two
bulky side chains which shown low micromolar cytotoxicity in a
panel of five PCa cell lines and potently suppressed DHT-induced
transactivation of the WT and the T877A, W741C, and H874Y
mutated ARs. Molecular modeling indicated that 4 adopts a “Y”-
shape conformation and forms multiple hydrogen bonds with
AR backbone in HBP (Zhou et al., 2009). Besides, via the SAR
studies of the lead compound DIMN, Yang et al have synthesized
a series of nicotinamides with extended linear scaffold bearing
sterically bulky alkoxy groups on isoquinoline end and identified
compounds 5 and 6 (Figure 4) as promising candidates of second
generation antiandrogen for advanced PCa (Yang et al., 2013).
Interestingly, Endo et al have developed a series of carborane
substituted antiandrogens (Fujii et al., 2005; Goto et al., 2005,
2010; Ohta et al., 2008). Carborane (dicarba-closo-dodecaborane,
C2B10H12) is an icosahedral boron cluster, has a bulky spheri-
cal structure, exhibits remarkable thermal stability, and has high
hydrophobicity. (Armstrong and Valliant, 2007). By replacing the
hydrophobic ring such as the steroidal skeleton or the phenyl ring
in hydroxyflutamide or bicalutamide by carborane cage, thus dis-
position of the helix-12 by using steric repulsion between the
bulky carborane cage and several amino acid residues, mainly
M895 and F876, in the hydrophobic pocket of the AR LBD.
Several carborane containing antiandrogens showed the compa-
rable potency to the known antiandrogens hydroxyflutamide or
bicalutamide and exhibit pure AR full antagonistic property.
However, although there were a couple of successful exam-
ples, the bulky group strategy was somehow casted doubt (Duke
et al., 2011). For example, several DHT-derived molecules bear-
ing one bulky chain surprisingly turned out to be potent ago-
nists of the AR. The complex structure of the AR LBD and one
of the compounds termed EM5744 (Figure 4) (PDB-ID, 2pnu)
was solved, which indicates the H12 of AR adopts the agonistic
position (Cantin et al., 2007). Besides, a crystal structure (PDB-
ID: 3rll) of compound 8 (Figure 4) complexed with AR (T877A)
shown that receptor accommodated the added bulky groups such
as phenyl to naphthyl substitution (Duke et al., 2011). The failure
of the bulky ligand strategy might due to the flexibility of HBP,
since it was reported that the volume of HBP would be hugely
increased upon the binding of the ligands and the recruitment of
coactivators (Xu et al., 2011).
Structure Based Antiandrogen Design Targeting
HBP
Recently, structural based molecular modeling has been
developed to predict target mutation-induced drug resistance.
Meanwhile, various structural based design strategies, including
targeting protein backbone, targeting highly conserved residues
and dual/multiple targeting, have been used to design novel
inhibitors for combating the drug resistance (Hao et al., 2012).
To date, there are 89 AR LBD structures deposited in Protein
Database Bank (PDB, www.pdb.org), which facilitate the discov-
ery and development of novel antiandrogens to combat the drug
resistance by using “structure-based” drug design (Figure 3B).
The molecular modeling techniques, especially molecular
dynamics, have been widely used to predict the conforma-
tional displacement of H12 when the mutant occurs. Zhou et
FIGURE 4 | Chemical structures of AR Antagonists and Agonists designed by using bulky group strategy.
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al investigated the impact of the T877A mutation on ligand-
induced helix-12 positioning by replica-exchange molecular
dynamics (REMD) simulations and proposed a REMD based
methodology to predict agonist/antagonist potency of a ligand.
According to the simulation results, a novel flutamide derivative
called SC333 (Figure 5) was designed and predicted to be a pure
antagonist of the T877A mutant, which was further experimen-
tally confirmed as a pan-antiandrogen against the wild type AR
and the T877A and W741C mutated ARs (Zhou et al., 2010). In
additional, Osguthorpe et al predicated that bicalutamide antago-
nizes AR by accessing an additional binding pocket (B-site) adja-
cent to the HBP via molecular dynamics, induced by displacing
H12(Osguthorpe and Hagler, 2011). These molecular modeling
studies based on crystal structure shed light on the mechanism
of the mutant-driven antagonist/agonist conversion and pro-
vide a structural framework for the design of novel antiandro-
gens (Osguthorpe and Hagler, 2011). An impressive work was
reported by Dr Sawyers and the collaborators recently (Balbas
et al., 2013). They performed molecular dynamics simulations of
antiandrogen-AR complexes and suggested the mechanism that
the F876L substitution alleviates antagonism through reposition-
ing of the coactivator recruiting H12. Based on the mechanism, a
focused chemical screening was performed and three novel com-
pounds, including the most potent compound DR103 (Figure 5),
were identified effectively antagonizing AR F876L (and AR WT)
to suppress the growth of PCa cells lines resistant to enzalutamide
(Balbas et al., 2013).
Structure-based virtual screening is another effective way to
obtain the lead compound of antiandrogens. For example, com-
bining virtual screening and further biological assay, a lead com-
pound, VPC-3033 (Figure 5), was identified to demonstrated
strong androgen displacement potency which effectively inhib-
ited AR transcriptional activity possess, profoundly degraded
AR and significantly suppressed enzalutamide resistance PCa
cells (Li et al., 2013a). Moreover, through structure-based virtual
screening using the FlexX docking model, 54 candidates were
selected and further screened for AR antagonism via cell-based
tests. One compound, DIMN (Figure 5), showed antagonistic
effect specific to AR with comparable potency to that of hydrox-
yflutamide and bicalutamide (Song et al., 2012). In another vir-
tual screening work, the database was firstly filtered through a
pharmacophore models built according to the structures of the
reported antiandrogens, and the hits were subjected to structure-
based docking evaluations using an AR homology model and
cross-docked into the variant AR crystal structure bound to bica-
lutamide using the Surflex suite. A series of structural distinct
competitive AR antagonists were obtained, which belonged to
six chemotypes. Among these compounds, chemotype A com-
pounds functioned as AR antagonists in vivo in normalmalemice
and suppressed AR activity and tumor cell proliferation in human
CRPC xenografts (Shen et al., 2012). In addition, the molecular
docking was also applied to establish the binding mode of the
antiandrogens in HBP of the AR LBD, which would be benefi-
cial to further optimization of the lead compounds (Zhou et al.,
2009; Pepe et al., 2013; Guerrini et al., 2014).
Steroid or Non-Steroid Conjugates
Cross coupling and conjugation strategies are wildly applied
to develop the modulator with multivalent and heterobifunc-
tional constructs, which exhibit high affinity and specificity to
the biomolecular target (Lambert, 2013; Washburn et al., 2013)
(Figure 3C). To date, there are limited examples targeting the
AR with steroidal conjugates (Levine et al., 2014). Utilizing
conjugates dubbed PROteolysis TArgeting Chimeric moleculeS
(PROTACS), the first steroid conjugate PROTAC-5 (Figure 6) to
selectively induce AR degradation was developed, which consist
of three components: a targeting moiety (DHT), a linker, and a
recognition element for E3. Initial ex vivo studies showed that
PROTAC-5 successfully degraded AR without compromising
normal cell viability at a concentration of 25µM 9 (Schneekloth
et al., 2004). In addition, Hashimoto lab has developed Specific
andNongenetic IAPs-dependent Protein ERasers (SNIPERs) that
consist of a targeting moiety (DHT), linker, and a recogni-
tion element for IAPs. In human mammary tumor (MCF-7)
cells that express AR, SNIPER 13 (Figure 6), an AR targeting
compound, decreased AR protein levels at a concentration of
30µM. Recent studies from the Hannon group have discov-
ered the first metallo-based chemotherapeutic conjugates target-
ing AR. Ethisterone was conjugated to pyridines, quinolines, and
isoquinolines utilizing Sonogashira cross-coupling conditions.
Subsequent coordination to platinum (II) complexes yielded
FIGURE 5 | Chemical structures of AR Antagonists based on Structure of HBP.
Frontiers in Pharmacology | www.frontiersin.org 6 March 2015 | Volume 6 | Article 57
Tian et al. Rational antiandrogen design
FIGURE 6 | Chemical structures of steroid conjugate AR Antagonists.
metallo-based bifunctional agents. Initial evaluation of the cyto-
toxic effects of the two most promising metallo-based bifunc-
tional agents 15 and 16 (Figure 6), in the cell lines that express
AR revealed promising biological activity (IC50 = 15.9µM)
(Huxley et al., 2010). Essigmann’s group has developed heterob-
ifunctional DNA-damaging agent 17 (Figure 6) in which a alky-
lating agent N,N-bis-2-chloroethylaniline was linked to a steroid
hormone that targets AR, allowing the conjugate to simultane-
ously bind to AR and DNA, resulting in the blockade of DNA
repair enzymes in PCa cell lines that overexpressing AR, sub-
sequently leading to the disruption of AR-mediated transcrip-
tion and signaling (Marquis et al., 2005). An emerging avenue in
molecular pharmacology is the development of multivalent ther-
apeutic agents. Therefore, the Kirshenbaum lab designed multi-
valent ethisterone conjugates to specifically target the AR LDB
and modulate AR activity via different mechanisms of action.
Ethisterone was conjugated at the 17-α position to the peptoid
scaffold via highly stable triazole linakges. Two conjugates 18
and 19 (Figure 6) exhibited potent anti-proliferative properties
in proliferation studies of LNCaP-abl cell lines and no cytotoxi-
city in PC-3 and HEK293 cell lines, establishing that conjugates
selectively target AR (Levine et al., 2012).
Except for steroid conjugates, there are several representa-
tive examples of promising strategies that have been used to
target AR with non-steroidal conjugates. Recently, the Oyelere’s
lab reported a non-steroidal heterobifunctional conjugate 20
(Figure 7) outfitted with histone deacetylase inhibitors that
exhibit higher potency in modulation of AR activity than
clinically used anti-androgens (Gryder et al., 2013). In sim-
ilar studies, the Koch lab reported a non-steroidal heterob-
ifunctional conjugate 21 (Figure 7) containing doxorubicin,
a non-selective cytotoxic therapeutic DNA intercalator. The
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FIGURE 7 | Chemical structures of non-steroid conjugate AR Antagonists.
antiandrogen conjugate successfully delivered the doxorubicin-
formaldehyde Schiff base to cells overexpressing AR (Cogan
and Koch, 2003). The El-Sayed lab introduced the first non-
steroidal multivalent conjugate 22 (Figure 7) that selectively
target membrane-associated AR. Bicalutamide was conjugated
to gold nanoparticles. The multivalent compounds enhanced
potency by one order of magnitude, in comparison to the mono-
valent ligand, in PCa cells (Dreaden et al., 2012).
Challenges and Future Perspectives
Despite the great improvements h ave been made in the develop-
ment of antiandrogen circumventing mutation-based resistance,
it remains a big challenge. First of all, there is still no antagonis-
tic or apo AR LBD structure available, current LBD actually are
all agonistic, which add the hurdle of structure-based antiandro-
gen design. Up to now, the adopted antagonistic AR LBD model
included the homology model based on the antagonistic LBD of
other nuclear receptor such as ER, GR and PR, themodel with the
H12 simply deleted from the agonistic AR LBD, and the model
equilibrated via molecular dynamics from the started structure
of the agonistic AR LBD. Thus, the antagonistic or apo AR LBD
structure is highly in demand to provide more accurate model
in structural based drug design of antiandogens. However, as the
antagonistic or apo AR LBD protein is formidable to be pre-
pared and crystallized due to its flexibility and tight association
with the bacterial chaperonin (Bohl et al., 2005b), to solve the
3D structure of the antagonistic or apo AR LBD is still a huge
challenge. Secondly, besides of acquired the mutation of AR to
induce drug resistance, there are other mechanisms including
aberrant expression of AR co-regulators and alternative AR acti-
vation by cytokines and growth factors, and the expression of AR
splice variants lacking LBD. As an example, the cells with AR
gene rearrangements expressing both full-length and AR-Vs are
identified androgen independent and enzalutamide resistant, and
selective knock-down of AR-Vs expression inhibited androgen-
independent growth and restored responsiveness to androgens
and antiandrogens (Li et al., 2013b). Moreover, it was proposed
that the resistance to enzalutamide via the activation of AR and
its splice variants may be mediated by NF-kB2/p52 (Nadiminty
et al., 2013). Recent work revealed the enzalutamide resistance
could also be achieved through the activation of GR signaling
(Arora et al., 2013). Therefore, the drug resistance is associated
with multiple factors, and still a long trudge is left to circumvent
the antiandrogen resistance in prostate cancer.
Besides of HBP, several other binding sites on AR like AF2,
BF3, the DNA binding site, and AF1 have been attracted atten-
tions in novel antiandrogen development (Haendler and Cleve,
2012). To date, several ligands have been identified to bind to
these sites, and exhibiting potent activities in antagonizing the
AR signaling, which inhibit the proliferation of AR dependent
prostate cancer cells (Andersen et al., 2010; Axerio-Cilies et al.,
2011; Ravindranathan et al., 2013; Li et al., 2014; Munuganti
et al., 2014). Some of these active agents demonstrated significant
antiandrogen potency against enzalutamide-resistant prostate
cancer cell lines (Li et al., 2014; Munuganti et al., 2014). Espe-
cially, the agents that target the DNA binding site or AF1 could
effectively inhibit the growth of enzalutamide-resistant cells as
well as block the transcriptional activity of constitutively active
AR splice variants like AR-V7, ARv567 (Li et al., 2014). Thus,
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targeting these sites other than HBP provides an another feasible
avenue to develop the therapeutic agents for prostate cancer. As it
has been beyond the scope of current review, several comprehen-
sive reviews are recommended here (Nyronen and Soderholm,
2010; Haendler and Cleve, 2012; Lallous et al., 2013; Culig, 2014;
Tan et al., 2015; Lorente et al., 2015).
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